Document resource
Introduction Carotid webs (CWs), focal areas of intimal hyperplasia in the internal carotid artery, are increasingly recognized as a potential etiology for cryptogenic stroke, though have previously been reported to have a prevalence as low as 0.45% in ischemic stroke patients. Although their natural history and optimal management strategies are not yet completely understood, they are frequently treated given their increased risk of future ischemic events.Methods Consecutive patients treated with carotid artery stents (CAS) for CWs at three urban academic medical centers in the same health system from January 2022 to March 2026 were retrospectively reviewed. Patient demographics, risk factors, symptomatic presentation, National Institutes of Health Stroke Scale (NIHSS) at presentation, modified Rankin Scale (mRS) at presentation, laterality, presence of contralateral CW, time from TIA/stroke to stenting, 30-day recurrent stroke, and 30-day mRS were collected.Results A total of 1120 endovascular thrombectomies (EVTs) were completed and 23 patients (2.1%) later had 26 CWs treated with CAS. 92.3% of CWs were treated via femoral access. 65.2% (15/23) were female, with an average age of 51±10.4 years. 65.2% (15/23) had a history of hypertension, 21.7% (5/23) had a history of tobacco use, and 13.3% (2/15) of females were on hormonally active or oral contraceptive medications. 56.5% (13/23) underwent endovascular stroke thrombectomy at the time of presentation, with median NIHSS 13 (interquartile range [IQR] 6-16). The most common large vessel occlusion (LVO) locations for EVT were M1 (46.1%) and M2 (23.1%), with internal carotid artery (ICA) or tandem ICA-middle cerebral artery (MCA) occlusion the remainder. 92.3% were TICI 2B-3, with a median number of passes of 2 [IQR 1-2], and 61.5% were with contact aspiration alone. No CAS were placed acutely at the time of EVT. Median time from presentation to CAS placement was 16.5 days [IQR 5.8-47.5]. 3 (13.0%) patients were treated for asymptomatic contralateral CWs. No patients had procedural complications or recurrent stroke within 30 days of CAS. Median 30-day mRS was 1 [IQR 0-2]. 73.1% (19/26) had 6-month follow up and none experienced recurrent stroke.Conclusion CAS is a low-complication profile treatment option for CWs with low rate of recurrent stroke at 6 months. CWs may be found more commonly than previously reported in the stroke population.Disclosures J. Breton: None. H. Abbas: None. M. McCullough: None. A. Stemer: None. J. Mai: None. R. Tahir: None. D. Felbaum: None. S. Sur: None.